Ginkgo Bioworks Holdings, Inc. (DNA) is a publicly traded Healthcare sector company. As of May 20, 2026, DNA trades at $7.65 with a market cap of $481.44M and a P/E ratio of -1.42. DNA moved +4.76% today. Year to date, DNA is -12.97%; over the trailing twelve months it is -3.38%. Its 52-week range spans $5.00 to $17.58. Analyst consensus is sell with an average price target of $8.50. Rallies surfaces DNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ginkgo Bioworks Among Five in $58.76B Point-of-Care Diagnostics Market Growing 10%: Ginkgo Bioworks is named among five leading companies driving a $58.76B global point-of-care diagnostics market growing nearly 10% annually. Venture capital investments in digital health reached $4B in Q1, the highest first-quarter inflow since 2021, as backers shift from drug discovery to clinical-grade, decentralized testing platforms.
| Metric | Value |
|---|---|
| Price | $7.65 |
| Market Cap | $481.44M |
| P/E Ratio | -1.42 |
| EPS | $-5.36 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.58 |
| 52-Week Low | $5.00 |
| Volume | 617.81K |
| Avg Volume | 0 |
| Revenue (TTM) | $141.31M |
| Net Income | $-304.39M |
| Gross Margin | 0.00% |
3 analysts cover DNA: 0 strong buy, 1 buy, 0 hold, 2 sell, 0 strong sell. Consensus rating is sell. Average price target: $8.50.